Stereotaxis, Inc.

Stereotaxis, Inc.STXSEarnings & Financial Report

NYSE · Health Care · Electromedical & Electrotherapeutic Apparatus

Stereotaxis Inc. is an American publicly traded medical technology company based in St. Louis, Missouri, that makes robotic systems used by physicians to perform minimally-invasive endovascular procedures, including electrophysiology studies and cardiac catheter ablation procedures.

Revenue

$4.5M

Gross Profit

$3.3M

Operating Profit

$-6.0M

Net Profit

$-5.8M

Gross Margin

73.6%

Operating Margin

-133.7%

Net Margin

-129.6%

YoY Growth

-42.7%

EPS

$-0.07

Stereotaxis, Inc. Q2 FY2024 Financial Summary

Stereotaxis, Inc. reported revenue of $4.5M (down 42.7% YoY) for Q2 FY2024, with a net profit of $-5.8M (down 17.7% YoY) (-129.6% margin). Cost of goods sold was $1.2M, operating expenses totaled $9.3M.

Key Financial Metrics

Total Revenue$4.5M
Net Profit$-5.8M
Gross Margin73.6%
Operating Margin-133.7%
Report PeriodQ2 FY2024

Revenue Breakdown

Stereotaxis, Inc. Q2 FY2024 revenue of $4.5M breaks down across 2 segments, led by Disposables Service And Accessories at $4.3M (94.7% of total).

SegmentRevenue% of Total
Disposables Service And Accessories$4.3M94.7%
Other$240.0K5.3%

Stereotaxis, Inc. Revenue by Segment — Quarterly Trend

Stereotaxis, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Disposables Service And Accessories and Other) has evolved quarter over quarter.

SegmentQ4 FY2025Q3 FY2025Q2 FY2025Q1 FY2025
Disposables Service And Accessories$5.3M$5.6M$5.8M$5.5M
Other$318.0K

Stereotaxis, Inc. Annual Revenue by Year

Stereotaxis, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $32.4M).

YearAnnual Revenue
2025$32.4M
2024$26.9M
2023$26.8M
2022$28.1M

Stereotaxis, Inc. Quarterly Revenue & Net Profit History

Stereotaxis, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q4 FY2025$8.6M+36.3%$-5.5M-64.0%
Q3 FY2025$7.5M-18.8%$-6.5M-86.6%
Q2 FY2025$8.8M+95.4%$-3.8M-43.5%
Q1 FY2025$7.5M+8.6%$-5.8M-77.9%
Q4 FY2024$6.3M+38.9%$-7.5M-118.5%
Q3 FY2024$9.2M+17.9%$-6.2M-67.3%
Q2 FY2024$4.5M-42.7%$-5.8M-129.6%
Q1 FY2024$6.9M+5.1%$-4.5M-65.5%

Income Statement

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Revenue$6.9M$4.5M$9.2M$6.3M$7.5M$8.8M$7.5M$8.6M
YoY Growth5.1%-42.7%17.9%38.9%8.6%95.4%-18.8%36.3%

Balance Sheet

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Assets$39.5M$36.0M$50.9M$46.7M$45.7M$41.2M$45.6M$52.3M
Liabilities$19.4M$19.3M$34.7M$35.3M$37.5M$34.4M$34.1M$33.5M
Equity$14.6M$11.4M$10.8M$6.1M$2.9M$1.5M$6.3M$13.5M

Cash Flow

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Operating CF$-2.3M$-3.1M$-4.3M$1.3M$-1.8M$-3.7M$-4.2M$-4.0M